Emerging Anti-Atherosclerotic Therapies

Cardiovascular disease (CAD) is the main cause of morbidity and deaths in the western world. The development of atherosclerosis underlying CAD development begins early in human life. There are numerous genetic and environmental risk factors accelerating its progression which then leads to the occurr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Gluba-Brzózka, Beata Franczyk, Magdalena Rysz-Górzyńska, Janusz Ławiński, Jacek Rysz
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	atherosclerosis cyclodextrins protein kinase inhibitors colchicine inhibitors of p38 mitogen-activated protein kinase (MAPK) lipid dicarbonyl scavengers Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/6e000468eb9b41a18ac3139d50f89430
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e000468eb9b41a18ac3139d50f89430
record_format	dspace
spelling	oai:doaj.org-article:6e000468eb9b41a18ac3139d50f894302021-11-25T17:53:29ZEmerging Anti-Atherosclerotic Therapies10.3390/ijms2222121091422-00671661-6596https://doaj.org/article/6e000468eb9b41a18ac3139d50f894302021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12109https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Cardiovascular disease (CAD) is the main cause of morbidity and deaths in the western world. The development of atherosclerosis underlying CAD development begins early in human life. There are numerous genetic and environmental risk factors accelerating its progression which then leads to the occurrence of acute events. Despite considerable progress in determining risk factors, there is still a lot of work ahead since identified determinants are responsible only for a part of overall CAD risk. Current therapies are insufficient to successfully reduce the risk of atherosclerosis development. Therefore, there is a need for effective preventive measures of clinical manifestations of atherosclerosis since the currently available drugs cannot prevent the occurrence of even 70% of clinical events. The shift of the target from lipid metabolism has opened the door to many new therapeutic targets. Currently, the majority of known targets for anti-atherosclerotic drugs focus also on inflammation (a common mediator of many risk factors), mechanisms of innate and adaptive immunity in atherosclerosis, molecule scavengers, etc. The therapeutic potential of cyclodextrins, protein kinase inhibitors, colchicine, inhibitors of p38 mitogen-activated protein kinase (MAPK), lipid dicarbonyl scavengers, a monoclonal antibody targeting interleukin-1β, and P-selectin inhibitors is still not fully confirmed and requires confirmation in large clinical trials. The preliminary results look promising.Anna Gluba-BrzózkaBeata FranczykMagdalena Rysz-GórzyńskaJanusz ŁawińskiJacek RyszMDPI AGarticleatherosclerosiscyclodextrinsprotein kinase inhibitorscolchicineinhibitors of p38 mitogen-activated protein kinase (MAPK)lipid dicarbonyl scavengersBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12109, p 12109 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atherosclerosis cyclodextrins protein kinase inhibitors colchicine inhibitors of p38 mitogen-activated protein kinase (MAPK) lipid dicarbonyl scavengers Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	atherosclerosis cyclodextrins protein kinase inhibitors colchicine inhibitors of p38 mitogen-activated protein kinase (MAPK) lipid dicarbonyl scavengers Biology (General) QH301-705.5 Chemistry QD1-999 Anna Gluba-Brzózka Beata Franczyk Magdalena Rysz-Górzyńska Janusz Ławiński Jacek Rysz Emerging Anti-Atherosclerotic Therapies
description	Cardiovascular disease (CAD) is the main cause of morbidity and deaths in the western world. The development of atherosclerosis underlying CAD development begins early in human life. There are numerous genetic and environmental risk factors accelerating its progression which then leads to the occurrence of acute events. Despite considerable progress in determining risk factors, there is still a lot of work ahead since identified determinants are responsible only for a part of overall CAD risk. Current therapies are insufficient to successfully reduce the risk of atherosclerosis development. Therefore, there is a need for effective preventive measures of clinical manifestations of atherosclerosis since the currently available drugs cannot prevent the occurrence of even 70% of clinical events. The shift of the target from lipid metabolism has opened the door to many new therapeutic targets. Currently, the majority of known targets for anti-atherosclerotic drugs focus also on inflammation (a common mediator of many risk factors), mechanisms of innate and adaptive immunity in atherosclerosis, molecule scavengers, etc. The therapeutic potential of cyclodextrins, protein kinase inhibitors, colchicine, inhibitors of p38 mitogen-activated protein kinase (MAPK), lipid dicarbonyl scavengers, a monoclonal antibody targeting interleukin-1β, and P-selectin inhibitors is still not fully confirmed and requires confirmation in large clinical trials. The preliminary results look promising.
format	article
author	Anna Gluba-Brzózka Beata Franczyk Magdalena Rysz-Górzyńska Janusz Ławiński Jacek Rysz
author_facet	Anna Gluba-Brzózka Beata Franczyk Magdalena Rysz-Górzyńska Janusz Ławiński Jacek Rysz
author_sort	Anna Gluba-Brzózka
title	Emerging Anti-Atherosclerotic Therapies
title_short	Emerging Anti-Atherosclerotic Therapies
title_full	Emerging Anti-Atherosclerotic Therapies
title_fullStr	Emerging Anti-Atherosclerotic Therapies
title_full_unstemmed	Emerging Anti-Atherosclerotic Therapies
title_sort	emerging anti-atherosclerotic therapies
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6e000468eb9b41a18ac3139d50f89430
work_keys_str_mv	AT annaglubabrzozka emergingantiatherosclerotictherapies AT beatafranczyk emergingantiatherosclerotictherapies AT magdalenaryszgorzynska emergingantiatherosclerotictherapies AT januszławinski emergingantiatherosclerotictherapies AT jacekrysz emergingantiatherosclerotictherapies
_version_	1718411867344338944

Emerging Anti-Atherosclerotic Therapies

Ejemplares similares